Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
39 participants
INTERVENTIONAL
2011-01-01
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
By testing if simple life style interventions, i.e., increased water or coffee intake, may affect vasopressin secretion, evaluated as copeptin, we will increase the knowledge as to whether such life style induced changes of copeptin may in turn lead to effects on glucose tolerance as well as on other cardiometabolic risk factors previously shown to be associated with high copeptin level. Thus, the study will lead to further understanding about vasopressin and copeptin release and how life style manipulation of the vasopressin system may influence glucose metabolism and other cardiometabolic risk factors in healthy individuals.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Day 2: After completion of the 24-h urine collection and ABPM, in the fasting state in the morning, office blood pressure will be measured and blood sampling for plasma copeptin, osmolality insulin, glucagon, glucose, creatinine and hsCRP measurement will be performed. Then, during a maximum time period of 20 minutes, subjects will ingest either 1L of water or 4 dL of coffee, or just 10 ml of water (time control). To map the acute coffee or water effect on copeptin, the experiment proceeds with repeated blood sampling every 30 minutes for 4 hours after the first coffee or water intake. Day 1 then continues with the rest of the daily intake, i.e., 2 L of water or 6 dL of coffee in addition to normal food and fluid intakes.
Day 3 to 7: 3 L water per day or 1 L of coffee per day are ingested (or nothing, in the control intervention) in addition to each subject's own food and fluid intake. On days 4 and 6, blood sampling for electrolyte and urea measurement and osmolality will be carried out for reasons of safety and compliance check.
Day 8: Fasting in the morning, office blood pressure, blood sampling (copeptin, osmolality, insulin, glucagon, glucose, creatinine, hsCRP) will be performed and a 24-h urine collection and ABPM will be started.
Day 9: The final examination will consist of clinical examination including office blood pressure and blood sampling (overnight fasting plasma copeptin, osmolality, insulin, glucagon, glucose, creatinine, hsCRP and OGTT), and end of 24-h urine collection and ABPM.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Water
At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 1 L of water (still bottled water) to map the acute water effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 2 L of extra water (i.e. in addition to each subject's habitual food and fluid intake).
Intervention day 2-7: 3 L extra water per day in addition to each subject's habitual food and fluid intake.
Water
Please see the associated arm description
Coffee
At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 4 dL of coffee to map the acute coffee effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 6dL of extra coffee (i.e. in addition to each subject's habitual food and fluid intake).
Intervention day 2-7: 1 L extra coffee per day in addition to each subject's habitual food and fluid intake.
Coffee
Please see the associated arm description
Control
At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest just 10 ml of water to map the acute effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with each subject's habitual food and fluid intake.
Intervention day 2-7: Each subject's habitual food and fluid intake.
Control
Please see the associated arm description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Water
Please see the associated arm description
Coffee
Please see the associated arm description
Control
Please see the associated arm description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Skane
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical research unit, Internal medicine department, Skåne University Hospital in Malmö
Malmo, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010_740
Identifier Type: -
Identifier Source: org_study_id